Chiltern has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.   With staff based in Japan, Korea and Southeast Asia, IDA has offers expertise in establishing regulatory and development pathways for Japan and implementing Pan Asian clinical trials to achieve both Japanese and global regulatory objectives. IDA’s experience in a broad range of therapeutic areas and its local knowledge and relationships will a...